Skip to main content
SpringerLink
Log in

Clinical Trials in Gynecologic Oncology: Cooperative Group Research

  • Chapter
Gynecologic Oncology

Part of the book series: Cancer Treatment and Research ((CTAR,volume 10))

  • 50 Accesses

Abstract

The appearance of anticancer drugs that were effective in animal tumor systems and also showed promise in human malignancies set the stage for development of a new specialty of medical oncology. At the same time, it was realized that clinical trials required to establish the effectiveness of drugs would not keep up with the anticipated flood of new agents unless investigators from several institutions collaborated. Since such cooperative endeavors required the expenditure of money, physicians sought funding to develop cooperative groups not restricted to a single system or disease. The original two purposes for which groups were developed were development of therapeutic concepts and the testing of chemical agents. Over the years the second purpose broadened to cover every method of dealing with cancer and later with precancerous lesions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hoogstraten B (ed): Cancer Research: Impact of the Cooperative Groups. New York: Mason Publishing, USA Inc, 1980.

    Google Scholar 

  2. Lewis GC. Jr, Slack NH, Mortel R, Bross ID: Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer. Gyn Oncol 2:368–376, 1978.

    Article  Google Scholar 

  3. Brady L, Blessing J, Homesley H, Lewis GC Jr: Radiotherapy (RT), chemotherapy (CT) and combined therapy in Stage III epithelial ovarian cancer. (For the Gynecologic Oncology Group.) Proc Am Assoc Cancer Res 20:218, 1979.

    Google Scholar 

  4. Brady LW, Blessing JA, Slayton RE, Homesley HD, Lewis GC Jr: Radiotherapy (RT), chemotherapy (CT), and combined therapy in Stage III epithelial ovarian cancer. (For the gynecologic Oncology Group.) Cancer Clinical Trials 2:111–120, 1979.

    Google Scholar 

  5. Hreshchyshyn MM, Norris HJ: Postoperative treatment of women with resectable ovarian cancer with radiotherapy, melphalan, or no further treatment. (For the Gynecologic Oncology Group.) Proc Am Assoc Cancer Res 18:195, 1977.

    Google Scholar 

  6. Hreshchyshyn MM, Norris HH, Park R, Lagasse LD, Blessing J: Postoperative treatment of women with resectable malignant and possibly malignant epithelial ovarian tumors with radiotherapy, melphalan, or no further treatment. Proc UA Int Contra Ca, Buenos Aires, 1978.

    Google Scholar 

  7. Hreshchyshyn MM, Park RC, Blessing JA, Norris JH, Levy D, Lagasse LD, Creasman WT: The role of adjuvant therapy in Stage I ovarian cancer. (From the Gynecologic Oncology Group.) American Journal of Obstetrics & Gynecology 138:139–145, 1980.

    CAS  Google Scholar 

  8. Lewis GC Jr, Blessing JA: Ovarian cancer. Use of multiple modality programs involving surgery, radiation therapy and chemotherapy. Cancer 40:588–594, 1977.

    Article  PubMed  Google Scholar 

  9. Blom J, Park R, Blessing J: Treatment of women with disseminated and recurrent ovarian carcinoma with single and multichemotherapeutic agents. (For the Gynecologic Oncology Group.) Proc Am Soc Clin Oncol 19:338, 1978.

    Google Scholar 

  10. Park RC, Blom J, DiSaia JP, Lagasse LD, Blessing JA: Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan, 5-fluorouracil and dactinomycin. (From the Gynecologic Oncology Group.) Cancer 45:25–29-2542, 1980.

    Article  Google Scholar 

  11. Slayton R, Hreshchyshyn M, Silverberg S, Blessing J: Response of malignant ovarian germ cell tumors to vincristine (V), dactinomycin (A) and cyclophosphamide (C). (For the Gynecologic Oncology Group.) Proc Am Soc Clin Oncol 18:311, 1977.

    Google Scholar 

  12. Slayton RE, Hreshchyshyn MM, Silverberg SG, Shingleton HM, Park RC, DiSaia PJ, Blessing JA: Treatment of malignant ovarian germ cell tumors: Response to vincristine, dactinomycin and cyclophosphamide. (Preliminary Report.) Cancer, 42:390–309, 1978.

    Article  PubMed  CAS  Google Scholar 

  13. Slayton RE, Johnson G, Brady L, Blessing J: Radiotherapy (RT) and chemotherapy (CT) in malignant tumors of the ovarian stroma (MTOS) (For the Gynecologic Oncology Group.) Proc Am Soc Clin Oncol 21:430, 1980.

    Google Scholar 

  14. Smith JP, Rutledge F: Advances on chemotherapy for gynecologic cancer. Cancer 36: 669–674, 1975.

    Article  PubMed  CAS  Google Scholar 

  15. Wallace HJ Jr, Hreshchyshyn MM, Blessing JA: Comparison of the therapeutic effects of adriamycin versus adriamycin and vincristine versus adriamycin and cyclophosphamide in the treatment of advanced carcinoma of the cervix. Proc Am Assoc Cancer Res 18:131, 1977.

    Google Scholar 

  16. Wallace HJ Jr, Hreshchyshyn MM, Wilbanks GD, Boronow RC, Fowler WC Jr, Blessing JA: Comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclosphosphamide in the treatment of advanced carcinoma of the cervix. Cancer Treatment Reports, 62:1435–1441, 1978.

    PubMed  Google Scholar 

  17. Rossof AH, Drukker BH, Talley RW et al.: Randomized evaluation of chlorambucil and melphalan in advanced ovarian cancer. Proc Am Assoc Cancer Res 17:300, 1976.

    Google Scholar 

  18. Thigpen T, Lagasse L, Bundy B: Phase II Trial of Cis-platinum in Treatment of Advanced Ovarian Adenocarcinoma (For the Gynecology Oncology Group.) Proc Am Assoc Cancer Res 20:84, 1979.

    Google Scholar 

  19. Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing JA: Cis-dichlorodiamminepla-tinum (II) in the treatment of gynecologic malignancies: Phase II trials by the Gynecologic Oncology Group. Presented 9/21/78 at the National Cancer Institute. Cancer Treatment Reports, 63:1549–1555, 1979.

    PubMed  CAS  Google Scholar 

  20. Thigpen JT, Lagasse L, Homesley H, Blessing JA: Cis-platinum in the treatment of advanced or recurrent adenocarcinoma of the ovary: A Phase II study of the gynecologic Oncology Group (submitted to Am J Clin Oncol).

    Google Scholar 

  21. Briscoe K, Posmantier M, Brown J, Kennedy BJ: Cis-diamminedichloroplatinum (II) and adriamycin in the treatment of advanced ovarian carcinoma. Proc Am Soc Clin Oncol 19:378, 1978.

    Google Scholar 

  22. Alberts DS, Moon TE, Stephans RA, Wilson H, Oishi N, Hilgers RD, O’Toole R, Thigpen JT: Randomized study of chemo-immunotherapy for advanced ovarian carcinoma: A preliminary report of a Southwest Oncology Group study. Cancer Treatment Reports, 63: 325–332, 1979.

    PubMed  CAS  Google Scholar 

  23. Sedlis A, Sall S: Micro-invasive carcinoma of uterine cervix clinical-pathological study (For the Gynecologic Oncology Group.) Proc Am Soc Clin Oncol 18:306, 1977.

    Google Scholar 

  24. Sedlis A, Sall S, Tsukada Y, Park R, Mangan C, Shingleton H, Blessing JA: Micro-invasive carcinoma of uterine cervix: A clinical-pathological study. (For the Gynecologic Oncology Group.) American Journal of Obstetrics and Gynecology 133:64–74, 1979.

    PubMed  CAS  Google Scholar 

  25. Lagasse LD, Creasman WT, Shingleton HM, Ford HJ, Blessing JA: Results and complications of operative staging in cervical cancer. (Experience of the gynecologic Oncology Group.) Gynecologic Oncology, 9:90–98, 1980.

    Article  PubMed  CAS  Google Scholar 

  26. DiSaia PJ, Levy D, Bundy B: A preliminary report on the treatment of women with cervical cancer, Stages IIB, IIIB, and IVA confined to the pelvis and/or para-aortic nodes with radiotherapy alone versus radiotherapy plus immunotherapy (intravenous C-parvum), Phase III. Presented at the 2nd International Meeting of Immunotherapy of Cancer at the NCI, 4/28–30/80. To be published in Proceedings of Immunotherapy Meeting. Terry W, Rosenberg S (eds). New York: Elsevier/North-Holland Biomedical Publishing Co.

    Google Scholar 

  27. Hreshchyshyn MM: (Report 1) Description of the GOG, its structure and functions. (Report 2) Treatment of women with cervical cancer Stage IIIB and IV confined to the pelvis with hydroxyurea or placebo both in combination with radiation therapy. (For the Gynecologic Oncology Group.) Gynecologic Oncology 3:251–257, 1975.

    Article  PubMed  CAS  Google Scholar 

  28. Hreshchyshyn MM, Aron BS, Boronow RC, Franklin EW III, Shingleton HM, Blessing JA: Hydroxyurea or placebo combined with radiation to treat Stage IIIB and IV cervical cancer confined to the pelvis. International Journal of Radiation Oncology, Biology and Physics 5:317–322, 1979.

    CAS  Google Scholar 

  29. Keys H, Blessing JA et al.: Hydroxy urea and radiation for Stage IIIB and IV cervix cancer: Analysis of recurrence patterns and radiation factors. International Journal of Radiation Oncology, Biology and Physics 6:1429, 1980.

    Google Scholar 

  30. Quagliana JM, O’Bryan RM, Baker L, Gottlieb J, Morrison FS, Eyre HJ, Tucker WG, Costanzi J: Phase II study of 5-azacytidine in solid tumors. Cancer Treatment Reports 61:51–54, 1977.

    PubMed  CAS  Google Scholar 

  31. Omura GA, Shingleton HM, Creasman WT, Blessing JA, Boronow RC: Chemotherapy of gynecologic cancer with nitrosoureas: A randomized trial of CCNU and methyl-CCNU in cancers of the cervix, corpus, vagina and vulva. Cancer Treatment Reports 62:833–835, 1978.

    PubMed  CAS  Google Scholar 

  32. Haas CD, Coltman CA, Gottlieb JA, Haut A, Luce JK, Talley RW, Samal B, Wilson HE, Hoogstraten B: Phase II evaluation of bleomycin. A Southwest Oncology Group Study. Cancer 38:8–12, 1976.

    Article  PubMed  CAS  Google Scholar 

  33. Tranum BL, Haut A, Rivkin S, Weber E, Quagliana JM, Shaw M, Tucker WG, Smith FE, Samson M, Gottlieb J: A Phase II study of methyl CCNU in the treatment of solid tumors. Cancer 35:1148–1153, 1975.

    Article  PubMed  CAS  Google Scholar 

  34. Thigpen JT, Homesley H, Prem K, Mladineo J: Phase II trial of piperazinedione in treatment of advanced squamous cell carcinoma of the cervix. Proc Am Assoc Cancer Res 19:162, 1978.

    Google Scholar 

  35. Stolinsky DC, Bateman JR: Further experience with hexamethylmelamine in the treatment of carcinoma of the cervix. Cancer Treatment Reports 60:907–911, 1976.

    Google Scholar 

  36. Thigpen T, Shingleton H: Phase II trial of Cis-platinum in treatment of advanced squamous cell carcinoma of the cervix. Proc Am Soc Clin Oncol 19:332, 1978.

    Google Scholar 

  37. Thigpen T, Shingleton H: Phase II trial of Cis-platinum in treatment of advanced squamous cell carcinoma of the cervix. (For the Gynecologic Oncology Group.) Proc Am Soc Clin Oncol 19:332, 1978.

    Google Scholar 

  38. Thigpen T, Shingleton H, Homesley H: Phase II trial of Cis-platinum as first or second line treatment for advanced squamous cell carcinoma of the cervix. (For the Gynecologic Oncology Group.) Proc Am Soc Clin Oncol 20:388, 1979.

    Google Scholar 

  39. Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J: Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Cancer 48:899–903, 1981.

    Article  PubMed  CAS  Google Scholar 

  40. Thigpen T, Shingleton H, Homesley H, DiSaia P, Lagasse L, Blessing J: Cis-diamminedichloroplatinum (II) in the treatment of advanced or recurrent cervix and uterine cancer: Phase II trials of the Gynecologic Oncology Group. Presented at Symposium on Cis-platinum, Atlanta 9/27–28/79. In: Cisplatin: Current Status and New Developments. Prestayko W, Crooke T, Carter K (eds). New York: Academic Press, 1980.

    Google Scholar 

  41. Slayton R, Creasman W, Bundy B: Phase II trial of VP-16 in treatment of advanced squamous cell carcinoma of the cervix. (For the Gynecologic Oncology Group.) Proc Am Soc Clin Oncol 20:365, 1979.

    Google Scholar 

  42. Slayton RE, Creasman WT, Petty W, Bundy B, Blessing J: A Phase II trial of VP-16 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary. (A Gynecologic Oncology Group Study.) Cancer Treatment Reports 63:2089–2092, 1979.

    PubMed  CAS  Google Scholar 

  43. Arseneau JC, Bundy B, Dolan T, Homesley H, DiSaia P: Phase II trial of Baker’s antifol (NSC 139, 105) in advanced cervical carcinoma. (For the Gynecologic Oncology Group.) Proc Am Soc Clin Oncol 21:424, 1980.

    Google Scholar 

  44. Arseneau JC, Bundy B, Dolan T, Homesley H, DiSaia P: Phase II study of Baker’s antifol (Triazinate, TZT, NSC-139, 105) in advanced squamous cell carcinoma of the cervix. (For the Gynecologic Oncology Group.) Am J Clin Oncol (CCT) 5:61–64, 1982.

    CAS  Google Scholar 

  45. Thigpen T, Ehrlich C, Blessing J: Phase II study of maytansine in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. Proc Am Soc Clin Oncol 21:424, 1980.

    Google Scholar 

  46. Thigpen, JT, Ehrlich CE, Conroy J, Blessing JA: Phase II Study of maytansine in the treatment of advanced or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study (submitted to Am J Clin Oncol).

    Google Scholar 

  47. Hoogstraten B, Hass CD, Haut A, Talley RW, Rivkin S, Isaacs BL: CCNU and bleomycin in the treatment of cancer. A Southwest Oncology Group Study. Medical and Pediatric Oncology 1:95–106, 1975.

    Article  PubMed  CAS  Google Scholar 

  48. Greenberg BR, Kardinal CG, Pajak TF, Bateman JR: Adriamycin vs adriamycin and bleomycin in advanced epidermoid carcinoma of the cervix. Cancer Treatment Reports 61:1383–1384, 1977.

    PubMed  CAS  Google Scholar 

  49. Baker LH, Opipari MI, Wilson H, Bottomley R, Coltman CA: Mitomycin C, Vincristine and bleomycin therapy for advanced cervical cancer. Obstet Gynecol 52:146–150, 1978.

    PubMed  CAS  Google Scholar 

  50. Slayton RE, Mladineo JP: Adriamycin (A) and Cis-diamminedichloroplatinum (DDP) in recurrent and mestastatic squamous cell carcinoma of the cervix. Proc Am Soc Clin Oncol 19:335, 1978.

    Google Scholar 

  51. Lewis GC Jr, Bundy B: Surgery for endometrial cancer. Presented at the American Cancer National Conference - Gynecologic Cancer, Los Angeles. Cancer 48:568–574, 1981.

    Article  PubMed  Google Scholar 

  52. Creasman WT, Boronow R, Morrow CP, DiSaia PJ, Blessing JA: Adenocarcinoma of the endometrium: Its metastatic lymph node potential. A Preliminary Report. (Gynecologic Oncology Group - George Lewis MD, Chairman). Gynecologic Oncology 3:239–243, 1976.

    Article  Google Scholar 

  53. Thigpen T, Torres J, Buchsbaum H: Phase II trial of adriamycin in the treatment of advanced endometrial adenocarcinoma. (For the Gynecologic Oncology Group.) Proc Am Soc Clin Oncol 18:352, 1977.

    Google Scholar 

  54. Thigpen T, Buchsbaum H, Mangan C, Blessing JA: Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. Cancer Treatment Reports 63:21–27, 1979.

    PubMed  CAS  Google Scholar 

  55. Horton J, Begg CB, Arseneau J, Bruckner H, Creech R, Hahn RG: Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treatment Reports 62:159–161, 1978.

    PubMed  CAS  Google Scholar 

  56. Ehrlich CE, Geary RE, Young PCM: The use of progesterone receptors in the treatment of recurrent endometrial cancer. In: Endometrial Cancer. Brush MG, King RJB, Taylor RW (eds). London: Bailliere-Teindall, 1978, pp 258–264.

    Google Scholar 

  57. Young PCM, Ehrlich CE: Progesterone receptors in human endometrial cancer. In: Steroid Receptors and the Management of Cancer. Cleveland, Ohio: CRC Press. (In press).

    Google Scholar 

  58. Ehrlich MD, Young PCM, Cleary RE: Progesterone receptors - A New approach to recurrent endometrial cancer. Proc Am Assoc Cancer Res 18:7, 1977.

    Google Scholar 

  59. Omura GA, Blessing JA: Chemotherapy of Stage III, IV and recurrent uterine sarcomas: A randomized trial of adriamycin (AD) versis AD-dimethyl triazeno imadazole carboxamide (DTIC). (For the Gynecologic Oncology Group.) Proc Am Assoc Cancer Res 19:26, 1978.

    Google Scholar 

  60. DiSaia PJ, Morrow CP, Boronow R, Creasman W, Mittelstaedt L: Endometrial sarcoma -Lymphatic spread pattern. American Journal of Obstetrics and Gynecology 130(1): 104–105, 1978.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. George C. Lewis Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Blessing
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John R. Kellner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts, USA

    C. Thomas Griffiths M.D.

  2. Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA

    Arlan F. Fuller Jr. M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1983 Martinus Nijhoff Publishers, Boston

About this chapter

Cite this chapter

Lewis, G.C., Blessing, J., Kellner, J.R. (1983). Clinical Trials in Gynecologic Oncology: Cooperative Group Research. In: Griffiths, C.T., Fuller, A.F. (eds) Gynecologic Oncology. Cancer Treatment and Research, vol 10. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3852-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-3852-9_11

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-3854-3

  • Online ISBN: 978-1-4613-3852-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation